Glycine vs Placebo for the Schizophrenia Prodrome

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Schizophrenia Prodrome

In brief

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Key facts

Study ID

NCT00291226

Run by

Yale University

People needed

8

Starts

2006-03-01

Expected to finish

2009-07-01

Last updated by the study team

2020-04-02

Who can join

Age: 13 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• meet SIPS criteria for schizophrenia prodrome

You may not qualify if…

• history of psychosis

Where it is running

• PRIME Clinic — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.